ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Jun 4, 2013
ASCO Reveals That Big Pharma Is Alive
Some good news from Bristol-Myers Squibb, Merck, GlaxoSmithKline, and Amgen showed the promise of immunotherapies for cancer treatment.
Jun 3, 2013
The IATA Boosts 2013 Forecast for Airline Industry Profits; Investors Should Not Be Tempted
The airline industry is among the worst we've ever seen. Investors should steer clear of this terrible group.
Jun 3, 2013
Look Out Below: Iron Ore Prices Keep Falling
With China’s economy “struggling,” iron ore prices will remain weak. Let’s take a look at how the miners intend to handle the situation.
Jun 3, 2013
Revisiting the Real Risks of Linn Energy
To some, Linn Energy is a high-yielding savior; to others, it’s a Ponzi scheme. Let’s take a look at the controversial name.
Jun 3, 2013
What Did We Learn About Apple from the All Things D Conference?
Apple’s CEO provided some interesting commentary on the computing goliath.
Jun 1, 2013
Valuentum's June Edition of Its Dividend Growth Newsletter!
The June edition of our Dividend Growth Newsletter is now available.
Jun 1, 2013
Market Swoons in Late Trading Friday
Valuentum members were well-positioned in advance of the recent market slide. Large cap technology offers the best valuation support, in our view.
May 31, 2013
Dividend Increases for the Week Ending May 31
A number of firms hiked their dividends this week.
May 30, 2013
M&A Boom?
We take a look at some potential acquisition targets.
May 30, 2013
Astronics Acquires Peco to Get Closer to Boeing
Best Ideas Newsletter holding Astronics acquired Peco for $136 million.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.